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Background: Total hip arthroplasty (THA) is a vital therapy for various hip joint diseases. However, patients have
lower hemoglobin level post-operatively, remarkably inconsistent with the measured blood loss. The inconsistence
is majorly attributed to hidden blood loss (HBL). In this study, we investigated the HBL and its influential factors
among patients after THA.
Methods: From January 2008 to June 2014, 322 patients (99 males and 223 females) undergoing THA were enrolled
in this study. All patients were assessed comprehensively before the operation. The demographic information of the
patients was collected. Intra-operative and post-operative blood loss was recorded, and then, the total perioperative
blood loss and the HBL were calculated. Influential factors were further analyzed by multiple and stepwise regression.
Results: The HBL was 429 ± 223 mL, with a percentage of 35.4% ± 11.0% in the total perioperative blood loss
(1,155 ± 377 mL). Multiple and stepwise regression analysis revealed that HBL was positively associated with body
mass index (BMI), blood transfusion volume, length of incision, change of hematocrit (HCT) between pre-operation
and post-operation but negatively associated with age. As compared to male patients, female patients had a risk of
increased HBL. Development displasia hip (DDH) patients had a less risk of HBL in all patients.
Conclusion: HBL is a significant portion of total blood loss in the patients after THA. Gender, age, BMI, blood
transfusion, length of incision, change of HCT, and diagnosis are influential factors of HBL.
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Total hip arthroplasty (THA) is one of the most important
treatments for many hip joint diseases, such as femoral
neck fracture (FNF), osteoarthritis (OA), rheumatoid arth-
ritis (RA), development displasia hip (DDH), and avascu-
lar necrosis of femoral head (ANFH) [1]. It is also a
procedure that frequently leads to massive blood loss. Pre-
vious studies showed that the total blood loss was in the
range of 1,023–1,785 mL [2-5] and 30%–69% of patients
needed blood transfusion after THA [6,7]. Keating and
Meding reported that transfusion is an independent risk
factor for post-operative complications, such as immune
disorder and infection [8].* Correspondence: yujiwang@sohu.com
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unless otherwise stated.In usual clinical practice, the blood loss measured after
THA includes merely the intra-operative blood loss and
the post-operative drainage. In spite of an apparently sat-
isfactory blood management on blood loss, patients still
have anemia. Liu et al. speculated that some potential
factors are not considered for anemia after THA, for ex-
ample, blood penetration into the tissues, blood accumu-
lation around the joint, as well as hemolysis [4].
The potential blood loss, called hidden blood loss
(HBL), is usually ignored. Until 2000, the concept of HBL
was formally put forward [9]. Several theories were pro-
posed to address it. Pattison et al. and Faris et al. initially
suggested that HBL may be attributable to hemolysis
[10,11]. But Erskine et al. proposed that the unexplained
loss went into tissue compartments by using labeled red
cells [12]. Recently, Bao et al. concluded that free fatty
acids generated from fatty emboli in blood circulation are
responsible for the HBL by peroxidation damage of mem-
brane molecules of RBC and hemoglobin [13]. Moreover,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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diagnosis [4], body mass index (BMI) [16], anticoagulants
[3,17], tranexamic acid [18,19], and even closed-suction
drainage [20], may influence HBL. However, the mecha-
nisms and influential factors for HBL following THA are
not fully clear, and some of them are still controversial. In
our study, we investigated the HBL and analyzed the influ-




A total of 322 patients (including 99 males and 223 fe-
males) with a complete history of disease and an average
age of 71 (35–94) years were recruited in this study. The
diagnosis of patients included FNF (65.5%), OA (8.1%),
ANFH (10.9%), RA (7.1%), and DDH (8.4%). All the pa-
tients underwent primary THA surgery which was per-
formed by one same orthopedic surgeon at Changzhou
No.2 People’s Hospital of Nanjing Medical University
from January 2008 to June 2014. Patients who under-
went previous operations on the hip were excluded. All
enrolled patients had no history of hematological dis-
eases which could affect severely blood coagulation. Var-
iables such as gender, age, height, weight, BMI, length of
incision, pre-operative and post-operative hematocrit
(HCT), intra-operative blood loss, post-operative drain
blood volume, transfusion blood volume, and reinfusion
volume of drained blood were recorded.
This study was reviewed and approved by the Ethics
Committee of Changzhou No.2 People’s Hospital. And
informed consent was received from all patients.
Intra-operative treatment
The surgery was performed under general anesthesia or
continuous epidural anesthesia. All the patients received a
standard operating procedure via the posterior-lateral in-
cision. Length of incision was within a range of 10 to
15 cm. The prosthetic types of implants were divided into
cemented and uncemented. The intra-operative blood loss
was calculated by weighing the used compresses and re-
cording the amount of blood in the suction bottle and the
filtrated drainage blood which was recycled and transfused
to patients by self-blood transfusion equipment during
operation.
Post-operative treatment
The drainage tube was removed 48 h after operation, and
the drainage volume was recorded as the post-operative
blood loss. During the post-operative period, hemostatic
such as tranexamic acid was not used and low molecular
weight heparin (LMWH) was routinely injected to prevent
deep venous thrombosis. Qiong Danshen injection tria-
zine (a kind of Chinese medicine) or cinepazide was usedto improve microcirculation and facilitate recovery of
patients. After removal of drainage tube, patients were
requested to take an x-ray in order to examine the loca-
tion of the prosthesis and encouraged to walk with a
walking aid.
Calculation of HBL
The patient’s blood volume (PBV) was calculated by
Gross formula: PBV = k1× h3 + k2 × w + k3, (h, height
(m); w, weight (kg); for male, k1 = 0.3669, k2 = 0.03219,
and k3 = 0.6041; for female k1 = 0.3561, k2 = 0.03308,
and k3 = 0.1833) [21]. The total perioperative blood loss
was calculated by multiplying PBV by the change of
HCT, and HBL was further calculated. The perioperative
blood loss was the sum of intra-operative blood loss,
post-operative drainage volume, transfusion volume, and
HBL.
Statistical analysis
Multiple and stepwise regression analysis was performed
to evaluate the influential factors of HBL using fourteen
independent variables, including seven qualitative vari-
ables (age, BMI, PT, blood transfusion volume, operation
time, length of incision, and change of HCT between
pre-operation and post-operation) and seven quantitative
variables (sex, hypertension, anesthesia method, prosthetic
type, anticoagulants, hemorheologic agent, and diagnosis).
In the quantitative variables, male, hypertension, general
anesthesia, uncemented prosthesis, nonuse of LMWH,
nonuse of hemorheologic agent, and FNF diagnosis were
set as “0”, others were converted into dummy variables. A
positive coefficient indicates a positive influence on the
dependent variable (HBL), whereas a negative coefficient
indicates a negative influence. All independent variables
were incorporated into the model using the method of
“Enter”. All statistical analyses were performed by SPSS
for Windows Ver.18.0 (SPSS Inc. IL, USA), and differences
at a level of P < 0.05 were identified statistically significant.
Results
Between January 2008 and June 2014, a total of 322 pa-
tients underwent unilateral primary THA were enrolled
consecutively in this study. Demographic data of patients
are summarized in Table 1. There are no differences in age,
BMI, and hospital stay between men and women (P > 0.05,
χ2 test). The data for operation time, length of incision,
intra-operative blood loss, wound drainage, re-infused
blood volume, hematocrit level loss, calculated blood loss,
HBL, total blood loss, and the percentage of HBL are
shown in Table 2. The mean total blood loss was 1,155 ±
377 mL, and the HBL was 429 ± 223 mL (35.4% ± 11.0% in
total blood loss), indicating a considerable amount of HBL.
To next examine the association between HBL and
fourteen influential factors as mentioned earlier, we
Table 3 Multiple linear regression analysis on influential
factors of HBL after THA
Variables Coefficients P values
Constant −807.9 0.000*
Quantitative variable
Age (y) −1.2 0.012*
BMI (kg/m2) 3.2 0.020*
PT (s) −0.4 0.881
Blood transfusion (mL) 0.3 0.000*
Operation time (m) −0.1 0.613
Length of incision (cm) 69.9 0.000*




Anesthesia method −9.5 0.336
Prosthetic type 16.5 0.182
Anticoagulants
LMWH (2,050 iu/day) 28.6 0.165
LMWH (4,100 iu/day) −15.2 0.291
Hemorheologic agent
Qiong Danshen injection triazine −5.9 0.552
Cinepazide −5.2 0.772
Diagnosis




BMI body mass index, PT prothrombin time, HCT hematocrit, LMWH low
molecular weight heparin, ANFH avascular necrosis of femoral head, RA
rheumatoid arthritis, DDH development displasia hip.
*P < 0.05.
Table 1 Patient’s demographic information
Parameters Male Female Total
Number of patients 99 223 322
Age (years)* 68 (35–92) 72 (44–94) 71 (35–94)
Height (m) 1.69 (0.05) 1.57 (0.05) 1.61 (0.07)
Weight (kg) 70.6 (10.3) 58.3 (9.2) 62.1 (11.1)
BMI (kg/m2) 24.6 (3.3) 23.5 (3.4) 23.8 (3.4)
Hospital stay (days)* 17 (9–36) 17 (8–37) 17 (8–37)
Other values are presented as mean (SD).
SD standard deviation.
*Values are presented as median.
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we found that the regression analysis is reliable (its imita-
tion degree is ideal, R = 0.941) and predictive (P < 0.001). As
shown in Table 3, the following influential factors were
positively correlated with HBL: BMI (P = 0.020), blood
transfusion volume (P < 0.001), length of incision (P <
0.001), and change of HCT (P < 0.001). In contrast, age was
negatively associated with HBL (P = 0.012). As compared to
male patients, female patients had a risk of increased HBL
(P = 0.033). DDH patients had a less risk of HBL in all pa-
tients (P = 0.030). However, it appeared that prothrombin
time, operation time, hypertension, anesthesia method,
prosthetic type, and use of LMWH or hemorheologic
agents were not significantly correlated with HBL.
Discussion
Although there are some reports on HBL after arthro-
plasty surgery, mostly focusing on total knee arthroplasty
(TKA) but much less on THA, a systematic investigation
on HBL after THA and its influential factors is lacking. In
this study, we performed a detailed retrospective inves-
tigation on 322 consecutively enrolled THA patients with
relatively complete clinical data and a relative reliableTable 2 Perioperative blood changed in the patients after
THA
Parameters Values
Number of patients 322
Operation time (min) 88 (26)
Length of incision (cm) 13.4 (1.6)
Intra-operative blood loss (mL) 411 (143)
Wound drainage (mL) 314 (157)
Reinfused blood (mL) 604 (389)
Hematocrit level loss (%) 14.3 (4.1)
Calculated blood loss (mL) 551 (196)
Hidden blood loss (mL) 429 (223)
Total blood loss (mL) 1,155 (377)
Percentage of hidden loss in total (%) 35.4 (11.0)
Values are presented as mean (SD).approach for estimating HBL and further comprehensively
analyzed the influential factors of the HBL by the multiple
regression analysis.
Emerging data suggest that there is a significant
amount of HBL after THA, which is usually ignored in
the clinical practice for estimating perioperative blood
loss. For example, Sehat et al. reported that the mean
HBL after THA was 471 mL, being 26% of the total
blood loss [22]. Subsequently, using the same method of
calculating PBV, Liu et al. showed that the HBL in pa-
tients with FNF was 967 mL [4]. Similarly, in our study,
the volume of HBL was 429 ± 223 mL, with a percentage
of 35.4% ± 11.0% in total blood loss, indicating a consid-
erable amount. Previous studies provided some possible
explanations for the mechanisms of HBL. It was pro-
posed that the post-operative blood loss may be, at least
in part, arise from hemolysis [10]. Moreover, Faris et al.
further observed the increased levels of hemolysis by
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Consistently, our result showed that blood transfusion
can increase the HBL after THA, which is probably due
to hemolysis. Another explanation is that the HBL is
presumably ascribed to blood infiltration into tissue
compartments [12]. In our study, the length of incision
contributed to the HBL, possibly by blood infiltration.
Namely, the longer the incision was, the more pene-
trable tissue compartments forms. As a result, the blood
would be accumulated in these compartments, ultim-
ately leading to an increase in HBL.
Regarding influential factors for HBL, there are some
reports. For instance, Shen et al. reported that gender
and blood transfusion do not affect HBL in the patients
after TKA, but the use of tourniquet can reduce the
HBL [15]. However, Cushner and Friedman found that
gender plays a role in HBL, with greater contribution in
men relative to women. And they concluded that age,
diagnosis, operative time, and tourniquet time are not
associated with blood loss [14]. Additionally, there is evi-
dence that the amount of HBL is also associated with
diagnosis [4], BMI [16], and LMWH [17]. Our results
showed that gender, age, BMI, blood transfusion, length
of incision, change of HCT, and diagnosis are correlated
with the HBL after THA. Further, gender, length of inci-
sion, change of HCT, and diagnosis may have stronger
influences. Notably, the calculation method can also
affect the result of HBL. The Gross formula is a linear
model for circulating PBV by using the perioperative
hematocrit. It was initially introduced by Ward and then
improved by Gross [21]. Post-operative hematocrit is
one of the most important reference indexes to calculate
the HBL. Some researchers suggested the hematocrit
value 2–3 days after operation as an index [9,22]. Based
on our daily pre-operative and post-operative blood rou-
tine tests, we found that the lowest hematocrit value did
not occur on the second or third day after surgery in most
patients but on the fourth to seventh day. In agreement
with our result, it was reported that the hemoglobin (HB)
level of most patients initially declines and then increases
on the seventh day after arthroplasty surgery [15,23]. In
other words, the calculated PBV would be lower than the
actual volume if the hematocrit value is used as a refer-
ence 2–3 days after surgery, leading to underestimate the
HBL. Thus, we used the hematocrit value 4–7 days after
operation to calculate the HBL.
In this study, we could not rule out the influence of ra-
cial differences on our results because our subjects were
from the local native population. Additionally, we did not
use tranexamic acid, a common drug for hemostasis
which is routinely used in many surgeries. Recently, it was
reported that it can reduce post-operative blood loss and
transfusion rate after THA [24-26]. But as an antifib-
rinolytic, it had a potential thrombotic effect; thus, it wascontradicted in those patients at risk or with a history of
thrombosis [27]. In our hospital, the drug was not applied
routinely during the perioperative period and as a result
possibly leading to the increase of the perioperative blood
loss. Finally, other potential influential factors, such as the
cup size of implant and bone mineral density of patients,
which were not included in this study, need to be further
determined.
In conclusion, HBL is a significant portion of total blood
loss in the patients after THA. Gender, age, BMI, blood
transfusion, length of incision change of HCT, and diag-
nosis are influential factors of HBL in patients after THA.
However, the HBL appears not to be associated with
hypertension, anesthesia method, prosthetic type, pre-
operative prothrombin time, operation time, dosage of
LMWH post-operative, and use of blood-activating drug
post-operative. Lowest post-operative HCT should be used
for calculating the HBL. By focusing on these factors, fur-
ther clinical research should be done to reduce the HBL.
If HBL can be successfully controlled after surgery, the re-
habilitation of patients will be improved after THA.
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